Blood Tests for Alzheimer’s Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Blood Tests for Alzheimer’s Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance
Authors
Keywords
-
Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume -, Issue -, Pages 1-8
Publisher
IOS Press
Online
2022-04-27
DOI
10.3233/jad-215730
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
- (2022) Emma Nichols et al. Lancet Public Health
- Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
- (2022) Thomas K. Karikari et al. Nature Reviews Neurology
- Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
- (2021) Nicholas J. Ashton et al. ACTA NEUROPATHOLOGICA
- Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study
- (2021) Adam M. Brickman et al. Alzheimers & Dementia
- The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
- (2021) N. J. Ashton et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
- (2021) Henrik Zetterberg et al. Molecular Neurodegeneration
- African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants
- (2021) Suzanne E. Schindler et al. Neurology-Genetics
- Plasma P‐tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease
- (2021) Joyce R. Chong et al. Alzheimers & Dementia
- Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias
- (2021) Daniel Alcolea et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Meaningful collaborations can end ‘helicopter research’
- (2021) Fernanda Adame NATURE
- Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy
- (2021) Michel J. Grothe et al. NEUROLOGY
- A multicentre validation study of the diagnostic value of plasma neurofilament light
- (2021) Nicholas J. Ashton et al. Nature Communications
- TRAILBLAZER‐ALZ Study: Dynamics of amyloid reduction after donanemab treatment
- (2021) Sergey Shcherbinin et al. Alzheimers & Dementia
- Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview
- (2021) Constance Delaby et al. Alzheimers & Dementia
- Alzheimer's disease biomarkers in Black and non‐Hispanic White cohorts: A contextualized review of the evidence
- (2021) Carey E. Gleason et al. Alzheimers & Dementia
- Alzheimer disease in African American individuals: increased incidence or not enough data?
- (2021) Lisa L. Barnes Nature Reviews Neurology
- Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
- (2021) Andréa L. Benedet et al. JAMA Neurology
- What the Aducanumab Approval Reveals About Alzheimer Disease Research
- (2021) Jennifer J. Manly et al. JAMA Neurology
- Bias and stereotyping among research and clinical professionals: Perspectives on minority recruitment for oncology clinical trials
- (2020) Soumya J. Niranjan et al. CANCER
- Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
- (2020) Thomas K Karikari et al. LANCET NEUROLOGY
- An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
- (2020) Nicholas J. Ashton et al. Nature Reviews Neurology
- Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline
- (2020) Juan Lantero Rodriguez et al. ACTA NEUROPATHOLOGICA
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
- (2020) Sebastian Palmqvist et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Blood Biomarkers: Democratizing Alzheimer’s Diagnostics
- (2020) Henrik Zetterberg et al. NEURON
- Addressing Health Disparities Among Minority Populations
- (2020) Consuelo H. Wilkins et al. JAMA Neurology
- Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative
- (2020) Thomas K. Karikari et al. MOLECULAR PSYCHIATRY
- Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
- (2020) Alexis Moscoso et al. BRAIN
- Social Stigma of People with Dementia
- (2020) Magdalena Rewerska-Juśko et al. JOURNAL OF ALZHEIMERS DISEASE
- Racial Bias in Pulse Oximetry Measurement
- (2020) Michael W. Sjoding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
- (2020) Shorena Janelidze et al. JAMA Neurology
- Assessment of Racial Disparities in Biomarkers for Alzheimer Disease
- (2019) John C. Morris et al. JAMA Neurology
- Ethnoracial differences in Alzheimer's disease from the FLorida Autopsied Multi-Ethnic (FLAME) cohort
- (2019) Octavio A. Santos et al. Alzheimers & Dementia
- High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
- (2019) Suzanne E. Schindler et al. NEUROLOGY
- Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study
- (2019) Annika Rosengren et al. Lancet Global Health
- NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
- (2018) Clifford R. Jack et al. Alzheimers & Dementia
- High performance plasma amyloid-β biomarkers for Alzheimer’s disease
- (2018) Akinori Nakamura et al. NATURE
- Trends in health inequalities in 27 European countries
- (2018) Johan P. Mackenbach et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Commentary: Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
- (2018) Thomas K. Karikari et al. Frontiers in Neurology
- Prevalence and determinants of undetected dementia in the community: a systematic literature review and a meta-analysis
- (2017) Linda Lang et al. BMJ Open
- Mixed pathology is more likely in black than white decedents with Alzheimer dementia
- (2015) Lisa L. Barnes et al. NEUROLOGY
- A Systematic Review of Barriers and Facilitators to Minority Research Participation Among African Americans, Latinos, Asian Americans, and Pacific Islanders
- (2013) Sheba George et al. AMERICAN JOURNAL OF PUBLIC HEALTH
- Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010
- (2012) Thomas G. Beach et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Race, socioeconomic status, and health: Complexities, ongoing challenges, and research opportunities
- (2010) David R. Williams et al. Annals of the New York Academy of Sciences
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started